Effettuare il login Iscriviti gratis

Acelrx Pharmaceuticals Inc Debt / Equity

Cos'è Debt / Equity di Acelrx Pharmaceuticals Inc?

Debt / Equity di Acelrx Pharmaceuticals Inc è 1.18

Qual è la definizione di Debt / Equity?



Il rapporto debito è un rapporto finanziario che indica la proporzione relativa del patrimonio netto e del debito utilizzato per finanziare le attività di una società.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Debt / Equity di aziende nel Health Care settore su NASDAQ rispetto a Acelrx Pharmaceuticals Inc

Cosa fa Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Aziende con debt / equity simili a Acelrx Pharmaceuticals Inc